InnoSer, an innovator in preclinical research services with operations in Diepenbeek, Belgium and Leiden, The Netherlands, is pleased to announce that it has entered into a final agreement to acquire Sylics, a contract research organisation (CRO) specialized in efficacy testing using rodent in vivo models of neurological and psychiatric diseases.
Through the acquisition, InnoSer International will expand its existing in vitro and in vivo preclinical services portfolio with a wide range of validated models to support preclinical neuroscience research. These in vivo models are supported with strong complementary capabilities such as proprietary behavioral testing, stereotactic surgery, EEG and EMG analysis, bioinformatics and specialized histopathology. Sylics’ operations, based in Bilthoven, will extend to InnoSer’s in vivo facilities in Leiden and the entire Sylics team will be integrated within InnoSer. Sylics’ Chief Executive Officer, Maarten Loos, will lead the newly integrated operations of InnoSer in the Netherlands.
“This acquisition is an important step in our strategy of building the leading preclinical neuroscience platform in Europe. We believe that the key to improving clinical success is to provide translatable preclinical models with highly sensitive and accurate analyses that generate reliable and translational data as early on as possible in the drug development process,” explains Jan Bartels, Chief Executive Officer of InnoSer International. “By combining the strengths and knowledge of our two companies, we can now offer researchers an extensive platform of relevant models and readouts for improved accuracy and predictability moving from the preclinical towards the clinical phase.”
Maarten Loos, Chief Executive Officer of Sylics, comments: “We are looking forward to the collaboration with the expert team at Innoser as it will allow our clients to evaluate their compounds within a wide range of newly integrated models and services. The combined expertise allows for rigorous testing in a range of additional therapeutic areas including, nephrology, immuno-oncology, and cardio-metabolic disease models. We will maintain our shared history of dedication to customer service and continue to serve complex needs within all stages of preclinical drug development”.